162 related articles for article (PubMed ID: 17785867)
1. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models.
Li Y; Williams ME; Cousar JB; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2007 Sep; 179(6):4263-71. PubMed ID: 17785867
[TBL] [Abstract][Full Text] [Related]
2. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
[TBL] [Abstract][Full Text] [Related]
3. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.
Beum PV; Kennedy AD; Williams ME; Lindorfer MA; Taylor RP
J Immunol; 2006 Feb; 176(4):2600-9. PubMed ID: 16456022
[TBL] [Abstract][Full Text] [Related]
4. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
Beum PV; Lindorfer MA; Taylor RP
J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
[TBL] [Abstract][Full Text] [Related]
5. Loss of CD20 and bound CD20 antibody from opsonized B cells occurs more rapidly because of trogocytosis mediated by Fc receptor-expressing effector cells than direct internalization by the B cells.
Beum PV; Peek EM; Lindorfer MA; Beurskens FJ; Engelberts PJ; Parren PW; van de Winkel JG; Taylor RP
J Immunol; 2011 Sep; 187(6):3438-47. PubMed ID: 21841127
[TBL] [Abstract][Full Text] [Related]
6. Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
Beum PV; Mack DA; Pawluczkowycz AW; Lindorfer MA; Taylor RP
J Immunol; 2008 Dec; 181(11):8120-32. PubMed ID: 19018005
[TBL] [Abstract][Full Text] [Related]
7. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
[TBL] [Abstract][Full Text] [Related]
8. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Foran JM; Rohatiner AZ; Cunningham D; Popescu RA; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson PW; Gisselbrecht C; Reyes F; Radford JA; Bessell EM; Souleau B; Benzohra A; Lister TA
J Clin Oncol; 2000 Jan; 18(2):317-24. PubMed ID: 10637245
[TBL] [Abstract][Full Text] [Related]
9. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
[TBL] [Abstract][Full Text] [Related]
10. Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.
Barth MJ; Mavis C; Czuczman MS; Hernandez-Ilizaliturri FJ
Clin Cancer Res; 2015 Oct; 21(19):4391-7. PubMed ID: 25964296
[TBL] [Abstract][Full Text] [Related]
11. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
[TBL] [Abstract][Full Text] [Related]
12. Development of a Murine model to dissect the CpG-oligonucleotide-enhancement of the killing of human B Cells by rituximab.
Buhé V; Pers JO; Marianowski R; Berthou C; Youinou P; Loisel S
J Autoimmun; 2010 Mar; 34(2):136-44. PubMed ID: 19726161
[TBL] [Abstract][Full Text] [Related]
13. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.
Beum PV; Kennedy AD; Li Y; Pawluczkowycz AW; Williams ME; Taylor RP
J Immunol Methods; 2004 Nov; 294(1-2):37-42. PubMed ID: 15604014
[TBL] [Abstract][Full Text] [Related]
14. A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.
Nijmeijer BA; van Schie ML; Halkes CJ; Griffioen M; Willemze R; Falkenburg JH
Blood; 2010 Dec; 116(26):5930-40. PubMed ID: 20844239
[TBL] [Abstract][Full Text] [Related]
15. Monocytes mediate shaving of B-cell-bound anti-CD20 antibodies.
Pedersen AE; Jungersen MB; Pedersen CD
Immunology; 2011 Jun; 133(2):239-45. PubMed ID: 21426340
[TBL] [Abstract][Full Text] [Related]
16. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.
Aue G; Lindorfer MA; Beum PV; Pawluczkowycz AW; Vire B; Hughes T; Taylor RP; Wiestner A
Haematologica; 2010 Feb; 95(2):329-32. PubMed ID: 19679883
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).
Winkler U; Jensen M; Manzke O; Schulz H; Diehl V; Engert A
Blood; 1999 Oct; 94(7):2217-24. PubMed ID: 10498591
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.
Bologna L; Gotti E; Da Roit F; Intermesoli T; Rambaldi A; Introna M; Golay J
J Immunol; 2013 Jan; 190(1):231-9. PubMed ID: 23225880
[TBL] [Abstract][Full Text] [Related]
19. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma: complement/rituximab interactions & clinical results in refractory CLL.
Klepfish A; Gilles L; Ioannis K; Rachmilewitz EA; Schattner A
Ann N Y Acad Sci; 2009 Sep; 1173():865-73. PubMed ID: 19758239
[TBL] [Abstract][Full Text] [Related]
20. Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.
Vincent M; Teppaz G; Lajoie L; Solé V; Bessard A; Maillasson M; Loisel S; Béchard D; Clémenceau B; Thibault G; Garrigue-Antar L; Jacques Y; Quéméner A
MAbs; 2014; 6(4):1026-37. PubMed ID: 25072059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
